Five-Year Clinical Outcomes of Inferior Quadrant Trabectome Surgery for Open Angle Glaucoma.
Weber Constance, Ludwig Elisabeth, Hundertmark Sarah, Brinkmann Christian Karl, Petrak Michael, Holz Frank G, Mercieca Karl
AI Summary
Inferior trabectome surgery is safe and somewhat effective for glaucoma, but most patients still require eye drops and many need further surgery for adequate pressure control.
Abstract
Prcis: This retrospective study of 264 eyes having inferior quadrant trabectome surgery confirms its safety and relative effectiveness. Most patients however still require IOP-lowering agents, and a considerable proportion may need additional glaucoma surgery.
Purpose
To report outcomes from a large single-center cohort of inferiorly-applied trabectome surgery.
Patients and methods: Retrospective review of patients undergoing trabectome surgery for chronic open angle glaucoma (COAG) at the University Eye Clinic Bonn, Germany, from 2012 to 2020.
Results
Two hundred sixty-four eyes of 206 patients with COAG were included. The mean review period was 45.43 (range 12-101) months. One hundred five eyes (39.8%) underwent standalone surgery, of which 74 were pseudophakic and 31 phakic. The mean preoperative IOP was 17.58 mm Hg (range 12-50 mm Hg). One hundred five eyes (39.8%) developed a 'failure event' according to pre-defined criteria at a mean interval of 14.8 months postoperative. In absolute terms, 211 patients (79.9%) had a long-term IOP >14 mm Hg at 7.6 months, 174 patients (65.9%) >16 mm Hg at 10.6 months, 127 patients (48.1%) >18 mm Hg at 10.9 months, and 77 patients (29.2%) >21 mm Hg at 11.1 months. Over a five-year period, overall mean IOP remained stable at 13 mm Hg. The majority of patients were still on glaucoma drops (the mean number reduced from 2.9 to 2.7 agents). Subgroup analyses showed that a higher preoperative IOP was a positive predictor for failure, whereas combined surgery (with phaco) had better IOP outcomes (16.5 mm Hg vs. 19.3 mm Hg, respectively). Forty-one patients (15.5%) developed minor complications: 22 had high postoperative IOP within 3 months, 11 developed a self-resorbing hyphema, and 6 had fibrinous uveitis.
Conclusions
Trabectome surgery is a safe and relatively effective procedure for lowering IOP, but most patients still need IOP-lowering agents, and a considerable proportion may need additional glaucoma surgery within a relatively short time. Inferior quadrant treatment may result in inferior IOP outcomes when compared with nasal quadrant surgery.
MeSH Terms
Shields Classification
Key Concepts6
Inferior quadrant trabectome surgery is a safe and relatively effective procedure for lowering intraocular pressure (IOP) in patients with chronic open angle glaucoma (COAG).
After inferior quadrant trabectome surgery, most patients with chronic open angle glaucoma still require IOP-lowering agents, with the mean number of agents reducing from 2.9 to 2.7.
A considerable proportion of patients undergoing inferior quadrant trabectome surgery for chronic open angle glaucoma may need additional glaucoma surgery within a relatively short time.
Combined inferior quadrant trabectome surgery with phacoemulsification had better IOP outcomes (16.5 mm Hg) compared to standalone inferior quadrant trabectome surgery (19.3 mm Hg) in patients with chronic open angle glaucoma.
A higher preoperative IOP was a positive predictor for failure in patients undergoing inferior quadrant trabectome surgery for chronic open angle glaucoma.
Minor complications occurred in 41 patients (15.5%) after inferior quadrant trabectome surgery for chronic open angle glaucoma, including high postoperative IOP within 3 months (22 patients), self-resorbing hyphema (11 patients), and fibrinous uveitis (6 patients).
Related Articles5
Microinvasive glaucoma surgery: A review of 3476 eyes.
Systematic ReviewStandalone Canaloplasty and Trabeculotomy Using the OMNI Surgical System in Eyes with Primary Open-Angle Glaucoma: A 36-Month Analysis from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight).
Cohort StudyEffectiveness and Safety of iStent Infinite Trabecular Micro-Bypass for Uncontrolled Glaucoma.
Clinical TrialThe case for standalone micro-invasive glaucoma surgery: rethinking the role of surgery in the glaucoma treatment paradigm.
ReviewImplantation of a CyPass Supraciliary Stent Combined With Targeted iStent Trabecular Microbypass Stents in a Phakic Patient With Primary Open-angle Glaucoma.
Case ReportIs this article assigned to the wrong chapter(s)? Let us know.